SCHEMBL288855

SCHEMBL288855

C[C@@](N)(C(=O)O)c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ACP3 P15309 1/20 0.46
NR4A1 P22736 1/20 0.44
NR4A2 P43354 1/20 0.44
NR4A3 Q92570 1/20 0.44
KIF11 P52732 1/20 0.43
PPARG P37231 3/20 0.43
PPARA Q07869 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP2C9 P11712 1/20 0.43
PPARD Q03181 1/20 0.43
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP1A2 P05177 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CDC25B P30305 1/20 0.40
PLK1 P53350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146376 1.00 KDM4E (0.50) KDM4EALDH1A1HSD17B10ACP3NR4A1
SCHEMBL198219 1.00 KDM4E (0.50) KDM4EALDH1A1HSD17B10ACP3NR4A1
SCHEMBL29608063 1.00 KDM4E (0.50) KDM4EALDH1A1HSD17B10ACP3NR4A1
SCHEMBL4963997 0.90 ALDH1A1 (0.45) KDM4EALDH1A1HSD17B10ACP3NR4A1
SCHEMBL7287554 0.85 KDM4E (0.53) KDM4EALDH1A1HSD17B10ACP3NR4A1
SCHEMBL27165013 0.85 KDM4E (0.39) KDM4EALDH1A1HSD17B10ACP3KIF11
SCHEMBL28252994 0.83 KIF11 (0.49) KDM4EALDH1A1KIF11TDP1MEN1
Norleucine SCHEMBL28063292 0.82 KIF11 (0.51) KDM4EALDH1A1HSD17B10KIF11TDP1
SCHEMBL27575255 0.82 KIF11 (0.40) KDM4EALDH1A1HSD17B10ACP3KIF11
SCHEMBL4678773 0.81 KDM4E (0.53) KDM4EALDH1A1HSD17B10ACP3NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1020 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459973-B2 Peptide compounds for reducing side effects of CB1 receptor agonists UNIVERSITAT DE BARCELONA (ES) 2025-11-04 US claimed
WO-2024197259-A1 TRANSCYTOTIC INTERCELLULAR GELATION ENABLES CELL SPHEROIDS BRANDEIS UNIVERSITY (US) 2024-09-26 WO claimed
EP-4041748-B1 PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS UNIV BARCELONA (ES) 2024-05-01 EP claimed
US-20240059737-A1 PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS UNIVERSITAT POMPEU FABRA (ES) 2024-02-22 US claimed
US-20230382949-A1 LINEAR APELIN RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2023-11-30 US claimed
CN-116710469-A Linear Apelin receptor agonists 赫帕雷斯治疗有限公司 2023-09-05 CN claimed
EP-4225773-A1 LINEAR APELIN RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2023-08-16 EP claimed
CN-116023438-A CXCR4 targeting polypeptide and application thereof 中国药科大学 2023-04-28 CN claimed
WO-2022079428-A1 LINEAR APELIN RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2022-04-21 WO claimed
EP-2922565-B1 SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR UNIV CINCINNATI (US) 2019-11-13 EP claimed
EP-0647449-A1 Sustained-release preparation of anti-endothelin substance Takeda Chemical Industries, Ltd. (JP) 1995-04-12 EP claimed
EP-0540676-B1 PEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY POLYGEN HOLDING CORP (US) 1994-11-17 EP claimed
EP-0398961-B1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY POLYGEN HOLDING CORP (US) 1994-11-02 EP claimed
EP-0417165-B1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY POLYGEN HOLDING CORP (US) 1994-01-26 EP claimed
EP-0552417-A1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP claimed
EP-0528312-A2 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-02-24 EP claimed
EP-0417165-A1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. EASTMAN KODAK CO (US) 1991-03-20 EP claimed
EP-0400051-A1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. EASTMAN KODAK CO (US) 1990-12-05 EP claimed
WO-1989010933-A1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY EASTMAN KODAK COMPANY (US) 1989-11-16 WO claimed
WO-1989007110-A1 POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY EASTMAN KODAK COMPANY (US) 1989-08-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459973-B2 Peptide compounds for reducing side effects of CB1 receptor agonists CNR2, CNR1, OPRD1 KDM4E 3865/4885ALDH1A1 2428/4885HSD17B10 3740/4885
US-20240059737-A1 PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS CNR2, CNR1, OPRD1 KDM4E 3719/4885ALDH1A1 2494/4885HSD17B10 3846/4885
US-20230382949-A1 LINEAR APELIN RECEPTOR AGONISTS APLNR, MTNR1A, EDNRA KDM4E 3435/4885ALDH1A1 2876/4885HSD17B10 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.